Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

68Ga-P16-093

Phase 2

FFirst Affiliated Hospital of Fujian Medical University

68Ga-P16-093 is one of 2 therapeutic programs targeting Prostate Cancer (Adenocarcinoma). It is currently in Phase 2.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[2][1]

Indication

Prostate Cancer (adenocarcinoma)Completed

Prostate Cancer (adenocarcinoma)Phase 2

Completed

Competition

Competitive Landscape

2 competitors in Prostate Cancer (adenocarcinoma)

#DrugCompanyPhaseTrials

Talzenna

68Ga-P16-093

FFirst Affiliated Hospital of Fujian Medical University

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer (Adenocarcinoma)1 trial

68Ga-P16-093 PET Imaging in the Diagnostic Study of Newly Diagnosed, Untreated Prostate Cancer, With a Head-to-head Comparison to mpMRI

Completed·FFirst Affiliated Hospital of Fujian Medical University·Phase 2·NCT07209865·82 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 68Ga-P16-093. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 68Ga-P16-093. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — First Affiliated Hospital of Fujian Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: FFirst Affiliated Hospital of Fujian Medical University

Related News